Results 131 to 140 of about 34,135 (204)

Epacadostat and Olaparib Synergistically Inhibit the Growth of BRCA-Proficient Triple-Negative Breast Cancer by Suppressing the Expression of BRCA1 and RAD51. [PDF]

Molecules
Huang L, Yang Y, Duan D, Dai L, Zhai B, Qian B.   +5 more
europepmc   +1 more source

Telmisartan increases olaparib efficacy in homologous recombination proficient tumors by augmenting type I interferon production. [PDF]

J Immunother Cancer
Murray CE, Ontiveros CO, Wentworth J, Blinkiewicz P, Leung B, Bai H, Spicer N, Holtz A, Tanner C, Balasubramanian A, Li W, Dray E, Zhao W, Curiel TJ.   +13 more
europepmc   +1 more source

Repression of EGFR by new biguanide 4C potentiated ovarian cancer to PARP inhibitors through down-regulation of BRCA2 and Rad51. [PDF]

Cell Death Dis
Xiao D, Yao J, Yang X, Xie Y, Zhou X, Li D, Peng M, Wang W, Zou H, Yang X.   +9 more
europepmc   +1 more source

Genome-wide CRISPR-Cas9 screening identifies CLK1 inhibition as a strategy to restore PARP inhibitor sensitivity via ERCC1 isoform switching. [PDF]

Protein Cell
Liu C, Xu F, Wu Y, Li J, Ni M, Xia S, Chen L, Zhao H, Yu M, Zhou Y, Zhang M, Li J, Wu X, Huang Y, Zhu T, Chen X.   +15 more
europepmc   +1 more source

Age-Related Differences in Severe Adverse Events During Maintenance Therapy with PARP Inhibitors: A Retrospective Cohort Study in Japanese Patients with Ovarian Cancer. [PDF]

Target Oncol
Nishimyo K, Ishikawa KB, Aoki D, Fushimi K, Yamazaki T.   +4 more
europepmc   +1 more source

Targeting de novo pyrimidine synthesis confers vulnerability to copper-mediated ATR inactivation in PARP inhibitor-resistant ovarian cancer. [PDF]

Nat Commun
Nan Y, Wang K, Hu M, Luo Q, Wu X, Yu X, Zhou X, Chen L, Li B, Cui Z, Liu Z.   +10 more
europepmc   +1 more source

LINC00467 mediates PARP inhibitor resistance in high-grade serous ovarian cancer by regulating miR-485-5p/RAD50 axis. [PDF]

J Ovarian Res
Li X, Xiang Y, Gao J, Zong H, Li M, Gao R, Zhang H.   +6 more
europepmc   +1 more source

Drastic Response to Olaparib in a Patient With Metastatic Castration-Resistant Prostate Cancer Harboring BRCA2 Alterations and Near-Threshold Tumor Mutational Burden. [PDF]

IJU Case Rep
Yokota K, Kosaka T, Daimon T, Fujiwara S, Nakamura K, Nishihara H, Oya M.   +6 more
europepmc   +1 more source

Durable complete radiographic and biochemical response to olaparib in BRCA2-mutated metastatic castration-resistant prostate cancer: a long-term responder case. [PDF]

Urol Case Rep
Ito F, Kobayashi K, Hayashi G, Kamijo S, Fujita T.   +4 more
europepmc   +1 more source

MOB2 Loss Sensitizes Lung Cancer Cells to PARP Inhibition Through p53-Dependent DNA Damage Signaling. [PDF]

Curr Issues Mol Biol
Gundogdu R.
europepmc   +1 more source